CXCL8 and familial pancreatic carcinoma: Nonetheless, the current antagonistic treatments targeting IL-8 struggle to achieve favorable clinical outcomes, implying that alternative mechanisms could have a significant impact on CAFs-induced platinum resistance in pancreatic cancer cells.